+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Antisense & RNAi Therapeutics Market Size, Share &Trends Analysis Report By Route of Administration (Pulmonary Delivery, Intravenous Injection), By Application (CVDs, Oncology), By Technology, And Segment Forecasts, 2019 - 2025

  • ID: 4538799
  • Report
  • 161 pages
  • Grand View Research
1 of 3

FEATURED COMPANIES

  • Acuitas Therapeutics
  • Dicerna Pharmaceuticals
  • Gradalis
  • miRagen Therapeutics
  • Quark Pharmaceuticals
  • Sanofi S.A
  • MORE
The global antisense & RNAi therapeutics market size is expected to reach USD 1.81 billion by 2025, growing at a CAGR of 7.5%, according to this report. Development in biological vectors and nanotechnology and rising external funding to conduct clinical studies pertaining to introduction of novel drug moieties play a vital role in the process of product development and fuel growth in this market.

Multinational healthcare establishments promote awareness and aid in finding novel therapies for treatment of different disorders. Private institutes such as California Institute of Regenerative Medicine and ALS Association that are involved in conducting trials by funding the research institutes and pharmaceutical organizations are expected to fuel sector growth significantly. Moreover, government initiatives for speeding the development of drug delivery platforms in order to reduce the disease burden are attributive for industrial growth.

Antisense & RNAi therapeutics services are applicable in treatment of several range of diseases that target the nucleic acid and affect cell growth cycle. miRNA is attracting considerable interest in its ability to restore gene expression and correct protein production thereby influencing industrial progress. Developments that involve research for utilization of different routes to deliver the desired effect of candidate moiety before its removal from blood are anticipated to fuel sector growth.

However, challenges associated with the drug delivery are expected to impede growth to certain extent. Delivery technologies that enable mitigation of the off-target effects and undesirable immunological stimulation need to be introduced to reduce the effect of restraining factors.

Further key findings from the study suggest:
  • Antisense RNA was the largest technology segment in 2018 owing to the advantages offered by this technology over the antisense technology
  • Based on the triggering of the RNA molecules this technology is segmented into siRNA and miRNA
  • Owing to significant involvement of miRNA in maintaining cell’s identity these are used to provide a deep insight into cancer metastasis
  • Usage of RNAi therapy to selectively target SNPs in genetic disorders is a major factor expected to provide this segment with a number of potential treatment avenues over the forecast period
  • siRNA is highly specific and allows induction at advanced stages of cancer growth as compared to chemotherapy, which is attributive for the largest share of oncology applications
  • Extensive R&D programs carried out in this sector to develop an efficient method for the delivery of RNA silencing therapeutic products is anticipated to propel growth
  • Ionis Pharmaceuticals, GSK, Alnylam Pharmaceuticals, Marina Biosciences, Sanofi-Genzyme, Quark Pharmaceuticals, Gene Signal, and Benitec Biopharma are major companies in the market

Please note: This product will be delivered within 48 business hours after receipt of order.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Acuitas Therapeutics
  • Dicerna Pharmaceuticals
  • Gradalis
  • miRagen Therapeutics
  • Quark Pharmaceuticals
  • Sanofi S.A
  • MORE
Chapter 1 Research methodology
1.1 Market segmentation & scope
1.2 Market definition
1.3 Information procurement
1.3.1 Purchased database
1.3.2 Internal database
1.3.3 Secondary sources & third party perspectives
1.3.4 Primary research
1.4 Information analysis
1.4.1 Data analysis models
1.5 Market formulation & data visualization
1.6 Data validation & publishing

Chapter 2 Executive Summary
2.1 Antisense & RNAi Therapeutics Market Outlook, 2014-2025

Chapter 3 Industry Outlook
3.1 Penetration & Growth Prospects Mapping
3.2 Trend analysis
3.2.1 Application trends
3.2.2 Product trends
3.2.3 End-use trends
3.2.4 Regional trends
3.3 Antisense & RNAi Therapeutics - Market Dynamics
3.3.1 Market driver analysis
3.3.1.1 Presence of strong pipeline product portfolio
3.3.1.2 Introduction of technological advancements in drug delivery
3.3.1.3 Implementation of favorable government initiatives & external funding for R&D exercises
3.3.1.4 Rising collaborations between pharmaceutical companies
3.3.2 Market restraint analysis
3.3.2.1 Expensive and tedious research programs
3.3.2.2 Delivery of RNAi therapeutics and off-target effects
3.4 Opportunity Analysis
3.5 Industry Analysis - Porter's
3.5.1 Supplier power - Medium
3.5.2 Buyer power - High
3.5.3 Substitution threat - Low
3.5.4 New entrants threat - Low
3.6 Regulatory landscape: Antisense & RNAi Therapeutics – SWOT by PEST Analysis
3.6.1 Political landscape
3.6.2 Economic landscape
3.6.3 Social landscape
3.6.4 Technology landscape
3.7 Company market share analysis
3.8 Competitive landscape
3.8.1 Strategy framework
3.8.2 Company categorization
3.8.2.1 New entrants
3.8.2.2 Mature players & leaders
3.9 Antisense & RNAi therapeutics Pipeline Analysis
3.9.1 Olix Pharmaceuticals
3.9.2 Glaxo Smith Kline
3.9.3 Sanofi Aventis / Genzyme
3.9.4 Alnylam Pharmaceuticals
3.9.5 Isis Pharmaceuticals/ Ionis Pharmaceuticals
3.9.6 Benitec Biopharma Ltd.
3.9.7 Arbutus Biopharma Ltd.
3.9.8 Silence Therapeutics
3.9.9 Bio-Path Holdings Inc.
3.9.10 Calando Pharmaceuticals
3.9.11 Gene Signal
3.9.12 iCo Therapeutics
3.9.13 Mirna Therapeutics/Synlogic
3.9.14 miRagen Therapeutics Inc.
3.9.15 Quark Pharmaceuticals
3.9.16 OncoGenex Pharmaceuticals Inc
3.9.17 Rexahn Pharmaceuticals
3.9.18 Biomarin/Prosensa
3.9.19 Regulus Therapeutics
3.9.20 Rxi Pharmaceuticals
3.9.21 Sarepta Therapeutics
3.9.22 Sylentis S.A.
3.9.23 Silenseed
3.9.24 Dicerna Pharmaceuticals
3.9.25 Santaris
3.9.26 Sirnaomics Inc.

Chapter 4 Antisense & RNAi Therapeutics Market Categorization: Technology Outlook
4.1 Antisense & RNAi Therapeutics Market Share, Technology, 2014 to 2025
4.2 RNA Interference Market, 2014 to 2025
4.2.1 RNA interference market revenue (USD Million), by North America
4.2.2 RNA interference market revenue (USD Million), by Europe
4.2.3 RNA interference market revenue (USD Million), by Asia Pacific
4.2.4 RNA interference market revenue (USD Million), by Latin America
4.2.5 RNA interference market revenue (USD Million), by Middle-East & Africa
4.2.6 siRNA market, 2014 to 2025
4.2.6.1 siRNA interference market revenue (USD Million), by North America
4.2.6.2 siRNA interference market revenue (USD Million), by Europe
4.2.6.3 siRNA interference market revenue (USD Million), by Asia Pacific
4.2.6.4 siRNA interference market revenue (USD Million), by Latin America
4.2.6.5 siRNA interference market revenue (USD Million), by Middle-East & Africa
4.2.7 miRNA market, 2014 to 2025
4.2.7.1 miRNA interference market revenue (USD Million), by North America
4.2.7.2 miRNA interference market revenue (USD Million), by Europe
4.2.7.3 miRNA interference market revenue (USD Million), by Asia Pacific
4.2.7.4 miRNA interference market revenue (USD Million), by Latin America
4.2.7.5 miRNA interference market revenue (USD Million), by Middle-East & Africa
4.3 Antisense RNA Market, 2014 to 2025
4.3.1 Antisense RNA interference market revenue (USD Million), by North America
4.3.2 Antisense RNA interference market revenue (USD Million), by Europe
4.3.3 Antisense RNA interference market revenue (USD Million), by Asia Pacific
4.3.4 Antisense RNA interference market revenue (USD Million), by Latin America
4.3.5 Antisense RNA interference market revenue (USD Million), by Middle-East & Africa

Chapter 5 Antisense & RNAi Therapeutics Market Categorization: Application Outlook
5.1 Global Antisense & RNAi Therapeutics Market Share, Application, 2014 to 2025
5.2 Oncology Market, 2014 to 2025
5.2.1 Antisense RNAi therapeutics in oncology market revenue (USD Million), by North America
5.2.2 Antisense RNA therapeutics in oncology market revenue (USD Million), by Europe
5.2.3 Antisense RNA therapeutics in oncology market revenue (USD Million), by Asia Pacific
5.2.4 Antisense RNA therapeutics in oncology market revenue (USD Million), by Latin America
5.2.5 Antisense RNA therapeutics in oncology market revenue (USD Million), by Middle-East & Africa
5.3 Cardiovascular Diseases Market, 2014 to 2025
5.3.1 Cardiovascular antisense market revenue (USD Million), by North America
5.3.2 Cardiovascular antisense market revenue (USD Million), by Europe
5.3.3 Cardiovascular antisense market revenue (USD Million), by Asia Pacific
5.3.4 Cardiovascular antisense market revenue (USD Million), by Latin America
5.3.5 Cardiovascular antisense market revenue (USD Million), by Middle-East & Africa
5.4 Respiratory Disorders Market, 2014 to 2025
5.4.1 Respiratory disorders antisense market revenue (USD Million), by North America
5.4.2 Respiratory disorders antisense market revenue (USD Million), by Europe
5.4.3 Respiratory disorders antisense market revenue (USD Million), by Asia Pacific
5.4.4 Respiratory disorders antisense market revenue (USD Million), by Latin America
5.4.5 Respiratory disorders antisense market revenue (USD Million), by Middle-East & Africa
5.5 Renal Diseases Market, 2014 to 2025
5.5.1 Renal diseases antisense market revenue (USD Million), by North America
5.5.2 Renal diseases antisense market revenue (USD Million), by Europe
5.5.3 Renal diseases antisense market revenue (USD Million), by Asia Pacific
5.5.4 Renal diseases antisense market revenue (USD Million), by Latin America
5.5.5 Renal diseases antisense market revenue (USD Million), by Middle-East & Africa
5.6 Neurodegenerative Disorders Market, 2014 to 2025
5.6.1 Neurodegenerative disorders antisense market revenue (USD Million), by North America
5.6.2 Neurodegenerative disorders antisense market revenue (USD Million), by Europe
5.6.3 Neurodegenerative disorders antisense market revenue (USD Million), by Asia Pacific
5.6.4 Neurodegenerative disorders antisense market revenue (USD Million), by Latin America
5.6.5 Neurodegenerative disorders antisense market revenue (USD Million), by Middle-East & Africa
5.7 Genetic Disorders Market, 2014 to 2025
5.7.1 Genetic disorders antisense market revenue (USD Million), by North America
5.7.2 Genetic disorders antisense market revenue (USD Million), by Europe
5.7.3 Genetic disorders antisense market revenue (USD Million), by Asia Pacific
5.7.4 Genetic disorders antisense market revenue (USD Million), by Latin America
5.7.5 Genetic disorders antisense market revenue (USD Million), by Middle-East & Africa
5.8 Infectious Diseases Market, 2014 to 2025
5.8.1 Infectious diseases antisense market revenue (USD Million), by North America
5.8.2 Infectious diseases antisense market revenue (USD Million), by Europe
5.8.3 Infectious diseases antisense market revenue (USD Million), by Asia Pacific
5.8.4 Infectious diseases antisense market revenue (USD Million), by Latin America
5.8.5 Infectious diseases antisense market revenue (USD Million), by Middle-East & Africa
5.9 Other Diseases Market, 2014 to 2025
5.9.1 Others diseases antisense market revenue (USD Million), by North America
5.9.2 Others diseases antisense market revenue (USD Million), by Europe
5.9.3 Others diseases antisense market revenue (USD Million), by Asia Pacific
5.9.4 Others diseases antisense market revenue (USD Million), by Latin America
5.9.5 Others diseases antisense market revenue (USD Million), by Middle-East & Africa

Chapter 6 Antisense & RNAi Therapeutics Market Categorization: Route of Administration Outlook
6.1 Global Antisense & RNAi Therapeutics Market Share, ROA, 2014 to 2025
6.2 Pulmonary Delivery Market, 2014 to 2025
6.2.1 Pulmonary delivery antisense market revenue (USD Million), by North America
6.2.2 Pulmonary delivery antisense market revenue (USD Million), by Europe
6.2.3 Pulmonary delivery antisense market revenue (USD Million), by Asia Pacific
6.2.4 Pulmonary delivery antisense market revenue (USD Million), by Latin America
6.2.5 Pulmonary delivery antisense market revenue (USD Million), by Middle-East & Africa
6.3 Intravenous Injections Market, 2014 to 2025
6.3.1 Intravenous injections antisense market revenue (USD Million), by North America
6.3.2 Intravenous injections antisense market revenue (USD Million), by Europe
6.3.3 Intravenous injections antisense market revenue (USD Million), by Asia Pacific
6.3.4 Intravenous injections antisense market revenue (USD Million), by Latin America
6.3.5 Intravenous injections antisense market revenue (USD Million), by Middle-East & Africa
6.4 Intra-dermal Injections Market, 2014 to 2025
6.4.1 Intra-dermal injections antisense market revenue (USD Million), by North America
6.4.2 Intra-dermal injections antisense market revenue (USD Million), by Europe
6.4.3 Intra-dermal injections antisense market revenue (USD Million), by Asia Pacific
6.4.4 Intra-dermal injections antisense market revenue (USD Million), by Latin America
6.4.5 Intra-dermal injections antisense market revenue (USD Million), by Middle-East & Africa
6.5 Intraperitoneal Injections Market 2014 to 2025
6.5.1 Intraperitoneal injections antisense market revenue (USD Million), by North America
6.5.2 Intraperitoneal injections antisense market revenue (USD Million), by Europe
6.5.3 Intraperitoneal injections antisense market revenue (USD Million), by Asia Pacific
6.5.4 Intraperitoneal injections antisense market revenue (USD Million), by Latin America
6.5.5 Intraperitoneal injections antisense market revenue (USD Million), by Middle-East & Africa
6.6 Topical Delivery Market 2014 to 2025
6.6.1 Topical delivery antisense market revenue (USD Million), by North America
6.6.2 Topical delivery antisense market revenue (USD Million), by Europe
6.6.3 Topical delivery antisense market revenue (USD Million), by Asia Pacific
6.6.4 Topical delivery antisense market revenue (USD Million), by Latin America
6.6.5 Topical delivery antisense market revenue (USD Million), by Middle-East & Africa
6.7 Other Route of Administration Market 2014 to 2025
6.7.1 Other ROA antisense market revenue (USD Million), by North America
6.7.2 Other ROA antisense market revenue (USD Million), by Europe
6.7.3 Other ROA antisense market revenue (USD Million), by Asia Pacific
6.7.4 Other ROA antisense market revenue (USD Million), by Latin America
6.7.5 Other ROA antisense market revenue (USD Million), by Middle-East & Africa

Chapter 7 Antisense & RNAi Therapeutics Market Categorization: Regional Outlook
7.1 Antisense & RNAi Therapeutics Market Share By Region, 2014 to 2025
7.2 North America
7.2.1 Antisense & RNAi Therapeutics market revenue, (USD million), by U.S.
7.2.2 Antisense & RNAi Therapeutics market revenue, (USD million), by Canada
7.2.3 U.S.
7.2.3.1 Antisense & RNAi Therapeutics market, by technology
7.2.3.2 Antisense & RNAi Therapeutics market, by application
7.2.3.3 Antisense & RNAi Therapeutics market, by ROA
7.2.4 Canada
7.2.4.1 Canada antisense & RNAi therapeutics market, by technology
7.2.4.2 Canada antisense & RNAi therapeutics market, by application
7.2.4.3 Canada antisense & RNAi therapeutics market, by ROA
7.3 Europe
7.3.1 Antisense & RNAi Therapeutics market revenue, (USD million), by Germany
7.3.2 Antisense & RNAi Therapeutics market revenue, (USD million), by U.K.
7.3.3 Germany
7.3.3.1 Germany antisense & RNAi therapeutics market, by technology
7.3.3.2 Germany antisense & RNAi therapeutics market, by application
7.3.3.3 Germany antisense & RNAi therapeutics market, by ROA
7.3.4 U.K.
7.3.4.1 U.K. antisense & RNAi therapeutics market, by technology
7.3.4.2 U.K. antisense & RNAi therapeutics market, by application
7.3.4.3 U.K. antisense & RNAi therapeutics market, by ROA
7.4 Asia Pacific
7.4.1 Antisense & RNAi Therapeutics market revenue, (USD million), by Japan
7.4.2 Antisense & RNAi Therapeutics market revenue, (USD million), by China
7.4.3 Japan
7.4.3.1 Japan antisense & RNAi therapeutics market, by technology
7.4.3.2 Japan antisense & RNAi therapeutics market, by application
7.4.3.3 Japan antisense & RNAi therapeutics market, by ROA
7.4.4 China
7.4.4.1 China antisense & RNAi therapeutics market, by technology
7.4.4.2 China antisense & RNAi therapeutics market, by application
7.4.4.3 China antisense & RNAi therapeutics market, by ROA
7.5 Latin America
7.5.1 Antisense & RNAi Therapeutics market revenue, (USD million), by Brazil
7.5.2 Brazil
7.5.2.1 Brazil antisense & RNAi therapeutics market, by technology
7.5.2.2 Brazil antisense & RNAi therapeutics market, by application
7.5.2.3 Brazil antisense & RNAi therapeutics market, by ROA
7.6 MEA
7.6.1 Antisense & RNAi Therapeutics market revenue, (USD million), by South Africa
7.6.2 South Africa
7.6.2.1 South Africa antisense & RNAi therapeutics market, by technology
7.6.2.2 South Africa antisense & RNAi therapeutics market, by application
7.6.2.3 South Africa antisense & RNAi therapeutics market, by ROA

Chapter 8 Competitive Landscape
8.1 Olix Pharmaceuticals
8.1.1 Company Overview
8.1.2 Financial Performance
8.1.3 Product Benchmarking
8.1.4 Strategic Initiatives
8.2 GlaxoSmithKline Plc
8.2.1 Company overview
8.2.2 Financial Performance
8.2.3 Product Benchmarking
8.2.4 Strategic Initiatives
8.3 Sanofi S.A
8.3.1 Company Overview
8.3.2 Financial Performance
8.3.3 Product Benchmarking
8.3.4 Strategic Initiatives
8.4 Alnylam Pharmaceuticals
8.4.1 Company Overview
8.4.2 Financial Performance
8.4.3 Product Benchmarking
8.4.4 Strategic Initiatives
8.5 Ionis Pharmaceuticals
8.5.1 Company Overview
8.5.2 Financial Performance
8.5.3 Product Benchmarking
8.5.4 Strategic Initiatives
8.6 Benitec Biopharma Ltd.
8.6.1 Company Overview
8.6.2 Financial Performance
8.6.3 Product Benchmarking
8.6.4 Strategic Initiatives
8.7 Acuitas Therapeutics
8.7.1 Company Overview
8.7.2 Financial Performance
8.7.3 Product Benchmarking
8.8 Arbutus Biopharma (formerly known as Tekmira Pharmaceuticals)
8.8.1 Company Overview
8.8.2 Financial Performance
8.8.3 Product Benchmarking
8.8.4 Strategic Initiatives
8.9 Silence Therapeutics Plc
8.9.1 Company Overview
8.9.2 Financial Performance
8.9.3 Product Benchmarking
8.9.4 Strategic Initiatives
8.10 Enzon Pharmaceuticals Inc
8.10.1 Company Overview
8.10.2 Financial Performance
8.10.3 Product Benchmarking
8.11 Antisense Therapeutics Ltd.
8.11.1 Company Overview
8.11.2 Financial Performance
8.11.3 Product Benchmarking
8.11.4 Strategic Initiatives
8.12 Bio-Path Holdings Inc.
8.12.1 Company Overview
8.12.2 Financial Performance
8.12.3 Product Benchmarking
8.12.4 Strategic Initiatives
8.13 Calando Pharmaceuticals (Arrowhead Pharmaceuticals, Inc.)
8.13.1 Company Overview
8.13.2 Financial Performance
8.13.3 Product Benchmarking
8.13.4 Strategic Initiatives
8.14 Gene Signal
8.14.1 Company Overview
8.14.2 Financial Performance
8.14.3 Product Benchmarking
8.14.4 Strategic Initiatives
8.15 Gradalis
8.15.1 Company Overview
8.15.2 Financial Performance
8.15.3 Product Benchmarking
8.15.4 Strategic Initiatives
8.16 iCo Therapeutics
8.16.1 Company Overview
8.16.2 Financial Performance
8.16.3 Product Benchmarking
8.16.4 Strategic Initiatives
8.17 Lorus Therapeutics (Aptose Biosciences)
8.17.1 Company Overview
8.17.2 Financial Performance
8.17.3 Product Benchmarking
8.17.4 Strategic Initiatives
8.18 Marina Biotech
8.18.1 Company Overview
8.18.2 Financial Performance
8.18.3 Product Benchmarking
8.18.4 Strategic Initiatives
8.19 miRagen Therapeutics
8.19.1 Company Overview
8.19.2 Financial Performance
8.19.3 Product Benchmarking
8.19.4 Strategic Initiatives
8.20 Mirna Therapeutics Inc
8.20.1 Company Overview
8.20.2 Financial Performance
8.20.3 Product Benchmarking
8.20.4 Strategic Initiatives
8.21 OncoGeneX Pharmaceuticals
8.21.1 Company Overview
8.21.2 Financial Performance
8.21.3 Product Benchmarking
8.21.4 Strategic Initiatives
8.22 Quark Pharmaceuticals
8.22.1 Company Overview
8.22.2 Financial Performance
8.22.3 Product Benchmarking
8.22.4 Strategic Initiatives
8.23 Rexahn Pharmaceuticals
8.23.1 Company Overview
8.23.2 Financial Performance
8.23.3 Product Benchmarking
8.24 Regulus Therapeutics
8.24.1 Company Overview
8.24.2 Financial Performance
8.24.3 Product Benchmarking
8.25 Rxi Pharmaceuticals
8.25.1 Company Overview
8.25.2 Financial Performance
8.25.3 Strategic Initiatives
8.26 Santaris Pharma A/S (Roche)
8.26.1 Company Overview
8.26.2 Financial Performance
8.26.3 Strategic Initiatives
8.27 Sarepta Therapeutics
8.27.1 Company Overview
8.27.2 Financial Performance
8.27.3 Strategic Initiatives
8.28 Sirnaomics Inc.
8.28.1 Company Overview
8.28.2 Financial Performance
8.28.3 Strategic Initiatives
8.29 Dicerna Pharmaceuticals
8.29.1 Company Overview
8.29.2 Financial Performance
8.29.3 Strategic Initiatives
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Olix Pharmaceuticals
  • GlaxoSmithKline Plc
  • Sanofi S.A
  • Alnylam Pharmaceuticals
  • Ionis Pharmaceuticals
  • Benitec Biopharma Ltd
  • Acuitas Therapeutics
  • Arbutus Biopharma (formerly known as Tekmira Pharmaceuticals)
  • Silence Therapeutics Plc
  • Enzon Pharmaceuticals Inc
  • Antisense Therapeutics Ltd.
  • Bio-Path Holdings Inc.
  • Calando Pharmaceuticals (Arrowhead Pharmaceuticals, Inc.)
  • Gene Signal
  • Gradalis
  • iCo Therapeutics
  • Lorus Therapeutics (Aptose Biosciences)
  • Marina Biotech
  • miRagen Therapeutics
  • Mirna Therapeutics Inc
  • OncoGeneX Pharmaceuticals
  • Quark Pharmaceuticals
  • Rexahn Pharmaceuticals
  • Regulus Therapeutics
  • Rxi Pharmaceuticals
  • Santaris Pharma A/S (Roche)
  • Sarepta Therapeutics
  • Sirnaomics Inc.
  • Dicerna Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll